Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder.

Pharmacogenomics - 1 Nov 2015

Maciukiewicz Malgorzata, Marshe Victoria S, Tiwari Arun K, Fonseka Trehani M, Freeman Natalie, Rotzinger Susan, Foster Jane A, Kennedy James L, Kennedy Sidney H, Müller Daniel J

Abstract excerpt

AIM: This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression. PATIENTS & METHODS: Twenty SNPs in IL-1β, IL-2, IL-6, TSPO and BDNF were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Brain-Derived Neurotrophic Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder, Major

Share to Double-Blind Method

Share to Interleukin-1beta

Share to Interleukin-2

Share to Interleukin-6

Share to Receptors, GABA

Source

Identifiers

PMID: 26556688
DOI: 10.2217/pgs.15.136

Genes

BDNF
TSPO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder.PMID 26556688Read ↗

Genome-wide association studies of placebo and duloxetine response in major depressive disorder.Semantic proximity Read ↗

Association study of polymorphisms within inflammatory genes and methylation status in treatment response in major depressionSemantic proximity Read ↗

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder.Semantic proximity Read ↗

GWAS-based machine learning approach to predict duloxetine response in major depressive disorder.Semantic proximity Read ↗

The role of pro-inflammatory cytokine gene polymorphisms in major depressive disorder: a systematic review.Semantic proximity Read ↗

Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response.Semantic proximity Read ↗

Serotonin transporter gene, depressive symptoms, and interleukin-6.Semantic proximity Read ↗

Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.Semantic proximity Read ↗

Interleukin-1β (C-511T) Genetic Variant and Major Depressive Disorder: A Systematic Review.Semantic proximity Read ↗

Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder.Semantic proximity Read ↗

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.Semantic proximity Read ↗

Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.